Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained its Buy rating on AtriCure and raised the price target from $49 to $53, indicating a positive outlook for the company's stock.
October 30, 2024 | 5:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity has maintained its Buy rating on AtriCure and increased the price target from $49 to $53, suggesting a positive short-term outlook for the stock.
The increase in the price target from $49 to $53 by Canaccord Genuity reflects a positive sentiment towards AtriCure's future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100